This is a Canada news story, published by Global News, that relates primarily to Moderna news.
For more Canada news, you can click here:
more Canada newsFor more Moderna news, you can click here:
more Moderna newsFor more vaccine development news, you can click here:
more vaccine development newsFor more news from Global News, you can click here:
more news from Global NewsOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about vaccine development, you might also like this article about
newer mRNA shots. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest mRNA vaccines news, vaccine news, news about vaccine development, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
RSV vaccineGlobal News
•
76% Informative
Moderna 's vaccine for respiratory syncytial virus ( RSV ) in adults 60 years and older approved in Canada .
It is the country’s first authorized mRNA-based shot for the condition.
Earlier this week , British drugmaker GSK received approval for its RSV vaccine for adults aged between 50 and 59 years .
VR Score
80
Informative language
82
Neutral language
78
Article tone
formal
Language
English
Language complexity
63
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links